Business Wire

NJ-GARP/UNEP

12.7.2022 15:02:09 CEST | Business Wire | Press release

Share
GARP and UNEP Finance Initiative Share New Collaborative Paper on Climate Risk Management

The thought leadership arm of the Global Association of Risk Professionals (GARP), GARP Risk Institute (GRI), published a special climate risk report today created in collaboration with the United Nations Environment Programme Finance Initiative (UNEP FI).

Titled “Steering the Ship: Creating Board-Level Climate Dashboards for Banks ,” the paper offers a comprehensive framework for establishing board-level climate dashboards that can be used to report decision-useful climate information and metrics. Developed through insights from 50 top financial institutions, including BNP Paribas, Bradesco, ING, MUFG, Santander, TD Bank and Wells Fargo, it covers the “what,” “why,” and “how” of creating a climate dashboard while addressing some of the key related challenges banks are facing.

Within companies, boards play a pivotal role in steering their organization through the increasingly complex and challenging climate risk landscape. According to GARP's 2021 Climate Risk Management Survey , 92% of financial institutions report that their boards have oversight over climate risk management. But some supervisory reports have noted that boards lack appropriate management information and metrics with which to perform this oversight.

"As climate change risks increase worldwide, company boards will be critical in ensuring their firms remain resilient and on a path to net zero,” said Jo Paisley, president of GRI. “It is the board's responsibility to decide how it intends to oversee risk management policies and practices, and a climate dashboard is likely to become an increasingly useful way for the board to discharge this responsibility.”

The report clarifies the different types of boards within banks to ensure a common understanding of terminology, before discussing the range of perspectives that a bank board should consider, with examples of information relevant to each. It examines common challenges that banks face in creating dashboards, but also provides concrete direction for how to structure an effective climate dashboard, providing high-level and detailed examples of dashboards — both hypothetical and from published reports.

“Bank boards now have the tools to understand the impacts climate change will have on their business,” said Maxine Nelson, senior vice president of GRI. “A board-level dashboard with key climate metrics is an excellent way to start to convey the breadth and depth of issues that banks increasingly need to navigate and to help them align their business with the goals of the Paris Agreement.”

To access the full paper, visit GARP’s Climate Risk Resource Center .

About the Global Association of Risk Professionals

The Global Association of Risk Professionals is a non-partisan, not-for-profit membership organization focused on elevating the practice of risk management. GARP offers the leading global certification for risk managers in the Financial Risk Manager (FRM® ), as well as the Sustainability and Climate Risk (SCR® ) Certificate and ongoing educational opportunities through Continuing Professional Development. Through the GARP Benchmarking Initiative and GARP Risk Institute, GARP sponsors research in risk management and promotes collaboration among practitioners, academics, and regulators.

Founded in 1996, governed by a Board of Trustees, GARP is headquartered in Jersey City, N.J., with offices in London, Beijing, and Hong Kong. Find more information on garp.org or follow GARP on LinkedIn , Facebook , and Twitter .

Social Media:

https://www.facebook.com/GARPRisk

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release

AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye